Literature DB >> 15694195

VH gene analysis of primary CNS lymphomas.

Hendrik Pels1, Manuel Montesinos-Rongen, Carlo Schaller, Uwe Schlegel, Ingo G H Schmidt-Wolf, Otmar D Wiestler, Martina Deckert.   

Abstract

Primary CNS lymphomas (PCNSL) are highly malignant non-Hodgkin's lymphomas of B cell origin associated with a poor prognosis. These neoplasms show variable sensitivity to radio- and chemotherapy. A molecular basis for these differences in treatment responses has not yet been established for primary CNS lymphomas in a comprehensive series of patients. Here, we performed PCR analyses of the immunoglobulin (Ig) gene rearrangements of 18 PCNSL, including nine patients who responded well to therapy and nine patients who showed resistance to treatment. Variable gene segment distribution, mutation frequency of variable region genes, and clinical course were analyzed. Our data suggest a tendency towards a higher mean mutation frequency (17.2%) in patients responding to treatment and a lower mutation frequency (11.8%) in patients exhibiting a poor response to therapy, respectively. Furthermore, a restricted usage of the VH4 gene family was observed in the majority of nonresponding patients. To further validate the prognostic impact of these molecular parameters, studies in a larger cohort of patients will be required.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15694195     DOI: 10.1016/j.jns.2004.11.038

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

Review 1.  Pathophysiology of retinal lymphoma.

Authors:  Sarah E Coupland; Chi Chao Chan; Justine Smith
Journal:  Ocul Immunol Inflamm       Date:  2009 Jul-Aug       Impact factor: 3.070

Review 2.  Molecular pathology of lymphoma.

Authors:  S E Coupland
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

Review 3.  Pharmacotherapy for adults with tumors of the central nervous system.

Authors:  Nina F Schor
Journal:  Pharmacol Ther       Date:  2008-11-27       Impact factor: 12.310

4.  Primary vitreoretinal lymphomas display a remarkably restricted immunoglobulin gene repertoire.

Authors:  Nabila Belhouachi; Aliki Xochelli; Myriam Boudjoghra; Claude Lesty; Nathalie Cassoux; Christine Fardeau; Thi Ha Chau Tran; Sylvain Choquet; Bishnu Sarker; Caroline Houillier; Agusti Alentorn; Phuc LeHoang; Carole Soussain; Valerie Touitou; Helene Merle-Beral; Khe Hoang-Xuan; Bahram Bodaghi; Kostas Stamatopoulos; Frederic Davi
Journal:  Blood Adv       Date:  2020-04-14

5.  Integration of the B-Cell Receptor Antigen Neurabin-I/SAMD14 Into an Antibody Format as New Therapeutic Approach for the Treatment of Primary CNS Lymphoma.

Authors:  Moritz Bewarder; Maximilian Kiefer; Clara Moelle; Lisa Goerens; Stephan Stilgenbauer; Konstantinos Christofyllakis; Dominic Kaddu-Mulindwa; Natalie Fadle; Evi Regitz; Frank Neumann; Markus Hoth; Klaus-Dieter Preuss; Michael Pfreundschuh; Lorenz Thurner
Journal:  Front Oncol       Date:  2020-11-12       Impact factor: 6.244

6.  Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma.

Authors:  Keiichiro Hattori; Mamiko Sakata-Yanagimoto; Manabu Kusakabe; Toru Nanmoku; Yasuhito Suehara; Ryota Matsuoka; Masayuki Noguchi; Yasuhisa Yokoyama; Takayasu Kato; Naoki Kurita; Hidekazu Nishikii; Naoshi Obara; Shingo Takano; Eiichi Ishikawa; Akira Matsumura; Masafumi Muratani; Yuichi Hasegawa; Shigeru Chiba
Journal:  Cancer Sci       Date:  2018-11-18       Impact factor: 6.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.